Targeted therapy against v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) activating mutations, seen in around 10–22% of mucosal melanomas [8], has been tested in clinical trials but results have been underwhelming. This evidence concerns the gene KIT and melanoma.